Eli Lilly (LLY +2.40%) is gaining momentum in the GLP-1 drug market, having overtaken Novo Nordisk (NVO +1.28%) with its Mounjaro and Zepbound offerings. While Novo Nordisk recently introduced a GLP-1 pill, Eli Lilly’s upcoming GLP-1 drug, which may outperform current options, keeps the competitive landscape dynamic. Notably, even as low-cost generics of Novo Nordisk’s Wegovy flood the Indian market, Eli Lilly’s Mounjaro has still seen a 10% sales increase there, indicating robust demand.
This competition is crucial for investors as it highlights the potential for Eli Lilly to dominate the international GLP-1 market, where it reportedly holds over 50% market share. Analysts at Morgan Stanley suggest that Eli Lilly’s international growth prospects may be underestimated, especially as consumers prioritize effective weight-loss solutions.
For market professionals, the key takeaway is the potential mispricing of Eli Lilly’s stock, trading at a price-to-earnings ratio of 38x, down from a five-year average of 56x. This could present a compelling opportunity for growth investors to capitalize on the evolving GLP-1 landscape.
Source: fool.com